Spravato (esketamine) demonstrates superior efficacy compared to quetiapine extended-release in treatment-resistant major depressive disorder – Johnson & Johnson
An open-label, international study published in the New England Journal of Medicine found that patients receiving Spravato (esketamine) CIII nasal spray for treatment-resistant depression (TRD) were 1.54 times… read more.